|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,351.00 INR | -0.01% |
|
+0.40% | +0.40% |
| 24/12 | Concord Biotech Limited Announces Resignation of Hina Patel as Company Secretary and Compliance Officer, Effective January 21, 2026 | CI |
| 18/12 | Concord Biotech Names CFO | MT |
Company Valuation: Concord Biotech Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Capitalization 1 | 1,59,100 | 1,75,818 | 1,41,336 | - | - |
| Change | - | 10.51% | -19.61% | - | - |
| Enterprise Value (EV) 1 | 1,58,709 | 1,72,645 | 1,37,506 | 1,36,207 | 1,34,172 |
| Change | - | 8.78% | -20.35% | -0.94% | -1.49% |
| P/E ratio | 51.6x | 47.3x | 40.1x | 31.8x | 25.3x |
| PBR | 10.4x | 9.7x | 6.79x | 5.8x | 4.89x |
| PEG | 1.8x | 2.3x | -7.97x | 1.2x | 1x |
| Capitalization / Revenue | 15.6x | 14.7x | 11.2x | 9.03x | 7.63x |
| EV / Revenue | 15.6x | 14.4x | 10.9x | 8.7x | 7.24x |
| EV / EBITDA | 36.8x | 34.1x | 28x | 21.8x | 17.8x |
| EV / EBIT | 42x | 38.2x | 31.7x | 23.8x | 18.9x |
| EV / FCF | 88.3x | 129x | 48.8x | 39.4x | 30.6x |
| FCF Yield | 1.13% | 0.77% | 2.05% | 2.54% | 3.27% |
| Dividend per Share 2 | 8.75 | 10.7 | 11.85 | 13.93 | 16.1 |
| Rate of return | 0.58% | 0.64% | 0.88% | 1.03% | 1.19% |
| EPS 2 | 29.45 | 35.52 | 33.73 | 42.52 | 53.44 |
| Distribution rate | 29.7% | 30.1% | 35.1% | 32.8% | 30.1% |
| Net sales 1 | 10,169 | 12,001 | 12,632 | 15,656 | 18,523 |
| EBITDA 1 | 4,316 | 5,063 | 4,905 | 6,240 | 7,520 |
| EBIT 1 | 3,780 | 4,520 | 4,331 | 5,715 | 7,094 |
| Net income 1 | 3,081 | 3,716 | 3,617 | 4,570 | 5,715 |
| Net Debt 1 | -391.7 | -3,173 | -3,831 | -5,130 | -7,165 |
| Reference price 2 | 1,520.80 | 1,680.60 | 1,351.00 | 1,351.00 | 1,351.00 |
| Nbr of stocks (in thousands) | 1,04,616 | 1,04,616 | 1,04,616 | - | - |
| Announcement Date | 24/05/24 | 29/05/25 | - | - | - |
1INR in Million2INR
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 40.05x | 10.89x | 28.03x | 0.88% | 156.44Cr | ||
| 18.17x | 4.9x | 12.43x | 0.49% | 7.61TCr | ||
| 59.2x | 15.67x | 33.6x | -.--% | 6.2TCr | ||
| 43.53x | 6.83x | 22.35x | 0.54% | 5.72TCr | ||
| 22.49x | 4.1x | 11.91x | 2.63% | 5.67TCr | ||
| 16.24x | 2.69x | 8.48x | -.--% | 2.47TCr | ||
| 16.99x | 3.35x | 10.06x | -.--% | 2.07TCr | ||
| 81.48x | 9.75x | 87.9x | -.--% | 1.98TCr | ||
| 346.83x | 105.22x | 170.97x | - | 1.71TCr | ||
| -4.88x | 5.4x | -3.18x | -.--% | 1.54TCr | ||
| Average | 64.01x | 16.88x | 38.26x | 0.5% | 3.51TCr | |
| Weighted average by Cap. | 48.72x | 11.95x | 28.66x | 0.66% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- CONCORDBIO Stock
- Valuation Concord Biotech Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















